TheraRadar
← Back
Data updated: Jun 28, 2026

VILIN BIO MED

Generics
Pharmaceuticals

VILIN BIO MED is a generic drug manufacturer with 1 FDA-approved products.

2025
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

VILIN BIO MED's Key Drugs

VILIN BIO MED's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

VILIN BIO MED's Recent FDA Approvals

VILIN BIO MED secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA
2024-08-26
bortezomib
1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

VILIN BIO MED's Therapeutic Areas

Disease areas where VILIN BIO MED has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

VILIN BIO MED Pipeline Snapshot

Active clinical trials for VILIN BIO MED across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling